Options trading expert Wendy Kirkland’s free guide reveals the options trading principles that are as easy to implement as they are to learn and how using them could earn you thousands in extra income each month!

Download the guide here and see the difference!

Troy Ignelzi Biography and Net Worth

CFO of Karuna Therapeutics

Troy A. Ignelzi joined Karuna Therapeutics as Chief Financial Officer in March 2019, bringing more than 25 years of experience supporting companies in finance, business development and operations. He joins Karuna from scPharmaceuticals where he, in his role as Chief Financial Officer, helped oversee development from a privately-held clinical-stage company to a publicly-traded biopharma preparing for commercial launch. Prior to scPharmaceuticals, Mr. Ignelzi was a senior executive at Juventas Therapeutics, Esperion Therapeutics, and Insys Therapeutics, helping raise public/private capital, expand development pipelines through licensing/acquisition and advancing critical therapies, several of which are currently approved by the FDA. He also brings relevant commercial experience, having launched and promoted CNS therapies while at Eli Lilly. Mr. Ignelzi is a member of the board of directors at Vedanta Biosciences and CinCor.

Mr. Ignelzi holds a bachelor’s degree in Accounting from Ferris State University.

What is Troy A. Ignelzi's net worth?: The estimated net worth of Troy A. Ignelzi is at least $7.20 million as of May 23rd, 2023. Mr. Ignelzi owns 30,487 shares of Karuna Therapeutics stock worth more than $7,204,078 as of June 7th. This net worth evaluation does not reflect any other investments that Mr. Ignelzi may own. Learn More about Troy A. Ignelzi's net worth.
What is Troy A. Ignelzi's salary?: As the CFO of Karuna Therapeutics, Inc., Mr. Ignelzi earned a total compensation package of $4,513,517.00 in 2021. Mr. Ignelzi earned a salary of $430,000.00, options awards of $3,808,217.00, non-equity compensation of $266,600.00, and other compensation of $8,700.00. Learn More on Troy A. Ignelzi's salary.
How do I contact Troy A. Ignelzi?: The corporate mailing address for Mr. Ignelzi and other Karuna Therapeutics executives is 33 ARCH STREET SUITE 3110, BOSTON MA, 02110. Karuna Therapeutics can also be reached via phone at (857) 449-2244 and via email at [email protected]. Learn More on Troy A. Ignelzi's contact information.
Has Troy A. Ignelzi been buying or selling shares of Karuna Therapeutics?: In the last ninety days, Troy A. Ignelzi has sold $2,010,690.00 in shares of Karuna Therapeutics stock. Most recently, Troy A. Ignelzi sold 9,000 shares of the business's stock in a transaction on Tuesday, May 23rd. The shares were sold at an average price of $223.41, for a transaction totalling $2,010,690.00. Following the completion of the sale, the chief financial officer now directly owns 30,487 shares of the company's stock, valued at $6,811,100.67. Learn More on Troy A. Ignelzi's trading history.
Who are Karuna Therapeutics' active insiders?: Karuna Therapeutics' insider roster includes Stephen Brannan (Insider), James Healy (Director), Troy Ignelzi (CFO), Andrew Miller (COO), Laurie Olson (Director), Atul Pande (Director), Steven Paul (CEO), and Heather Preston (Director). Learn More on Karuna Therapeutics' active insiders.
Are insiders buying or selling shares of Karuna Therapeutics?: In the last twelve months, Karuna Therapeutics insiders bought shares 1 times. They purchased a total of 47,777 shares worth more than $5,878,482.08. In the last twelve months, insiders at the sold shares 25 times. They sold a total of 225,827 shares worth more than $46,929,693.30. The most recent insider tranaction occured on May, 23rd when CFO Troy A Ignelzi sold 9,000 shares worth more than $2,010,690.00. Insiders at Karuna Therapeutics own 16.2% of the company. Learn More about insider trades at Karuna Therapeutics.
Information on this page was last updated on 5/23/2023.

Troy A. Ignelzi Insider Trading History at Karuna Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/23/2023	Sell	9,000	$223.41	$2,010,690.00	30,487
1/18/2023	Sell	200	$200.14	$40,028.00	21,837
11/15/2022	Sell	16,500	$225.85	$3,726,525.00	9,970
10/3/2022	Sell	4,100	$231.18	$947,838.00	10,370
9/30/2022	Sell	10,500	$228.86	$2,403,030.00	14,470
8/9/2022	Sell	16,500	$227.83	$3,759,195.00	24,970
4/21/2022	Sell	40	$134.46	$5,378.40	24,970
4/19/2022	Sell	3,500	$130.81	$457,835.00	24,970
2/15/2022	Sell	1,500	$111.14	$166,710.00
11/8/2021	Sell	13,500	$152.32	$2,056,320.00
6/16/2021	Sell	2,600	$129.31	$336,206.00	15,248
6/14/2021	Sell	900	$132.52	$119,268.00	15,248
5/12/2021	Sell	200	$120.00	$24,000.00	20,000
5/10/2021	Sell	7,000	$110.07	$770,490.00	20,000
1/8/2021	Sell	8,000	$104.49	$835,920.00	21,000
11/9/2020	Sell	9,318	$105.48	$982,862.64	5,564
11/6/2020	Sell	564	$108.15	$60,996.60	5,564
9/8/2020	Sell	2,000	$73.30	$146,600.00	7,000
7/8/2020	Sell	8,000	$98.74	$789,920.00	6,000
6/15/2020	Sell	6,000	$89.75	$538,500.00	2,000
5/8/2020	Sell	7,500	$83.38	$625,350.00	7,500

Troy A. Ignelzi Buying and Selling Activity at Karuna Therapeutics

Karuna Therapeutics Company Overview

Karuna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. engages in business of research and development of therapies utilizing muscarinic cholinergic receptors to treat psychosis and cognitive impairment in numerous central nervous system disorders. The company was founded by Andrew Miller, Eric Elenko, and Peter Jeffrey Conn in July 2009 and is headquartered in Boston, MA.

Today's Range

Now: $232.03

$231.88

$238.13

50 Day Range

MA: $206.23

$176.32

$236.30

2 Week Range

Now: $232.03

$93.47

$278.25

Volume

330,060 shs

Average Volume

364,432 shs

Market Capitalization

$8.69 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.15

Successful Options Trading Begins With…

From Tradewins | Ad